Untitled

Abstract

Background: Hypertension is the most common disorder affecting different age groups of people. The increased blood pressure creates discomfort in the patients; these cardiovascular diseases are risky which can lead to "mortality and morbidity". Labetalol hydrochloride is an anti-hypertensive drug used to treat high blood pressure and Angina. These compounds possess less water solubility and low bioavailability (25%). Objective: The current study is aimed to develop Labetalol hydrochloride Liquisolid Tablets to enhance its solubility. Results: The in-vitro dissolution studies showed enhanced drug release at 98.43% with Avicel PH102 as carrier and 96.54% with Fujicalin as the carrier. Hence F3 with 98.43% drug release was considered the optimized formulation. The optimized formulation batch F3 was subjected to stability studies as per the ICH guidelines. There was no significant change observed. Conclusion:It can be concluded that labetalol hydrochloride was successfully incorporated as a liquisolid tablet by the direct compression method. The direct compression method employed was easy and can be widely used'. The powder blend of F3 containing avicel pH 102 as a carrier material showed excellent flow ability, liquid retention potential compared to the Fujicalin as a carrier. Hence F3 is considered optimized. The in-vitro drug release confirmed the enhanced drug release from the liquisolid tablets. The stability studies revealed the formulation was stable. INTRODUCTION:Hypertension is the most frequent condition that affects people of different ages. Hypertension is defined as a rise in blood pressure in the systemic arteries. The systolic blood pressure should not exceed 120 mm Hg, and the diastolic blood pressure should not exceed 80 mm Hg, which is considered normal.